NRG-GU005

Clinical Trial Title Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer
Trial Status Closed to Enrollment
Start Date 11/16/2017
Location Doctors & Locations
Trial Type Cancer - Adult Oncology
Specific Condition Prostate cancer
Description This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.
Eligibility Criteria

Eligibility Criteria

  • Previously untreated (no local therapy such as surgery, radiation cryotherapy, HIFU, etc.) localized adenocarcinoma of the prostate
  • Age ≥ 18
  • History and physical including a digital rectal exam 60 days prior to registration
  • ECOG Performance Status 0-1
  • MRI of pelvis within 90 days prior to registration
  • Bone scan as clinically indicated within 90 days prior to registration
  • Willingness and ability to complete the Expanded Prostate Cancer Index Composite questionnaire

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.
IRB Number Central IRB
Notes https://clinicaltrials.gov/ct2/show/NCT03367702?term=nrg+gu005
Principal Investigator Andrew Kee, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org